Form 4: GoodRx CEO Barnes Receives 1.3M RSU Grant

GoodRx Holdings, Inc. CEO and President Wendy Lynn Barnes was granted 1,331,557 restricted stock units, vesting quarterly over three years.

Summary

• Wendy Lynn Barnes, the Chief Executive Officer and President of GoodRx Holdings, Inc. (GDRX), reported changes in her beneficial ownership.
• On March 3, 2026, Barnes was granted 1,331,557 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of GoodRx Class A common stock.
• These RSUs will vest ratably in 12 equal quarterly installments, with the first vesting scheduled for April 15, 2026, contingent upon her continued service.
• Following this transaction, Barnes directly beneficially owns 427,993 shares of Class A Common Stock and 1,331,557 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies a significant equity grant to the CEO, aligning her interests with long-term shareholder value and indicating confidence in future performance, though it's a standard compensation event rather than a direct operational win.

Positives

• The grant of 1,331,557 Restricted Stock Units (RSUs) to the CEO aligns management's long-term financial interests with shareholder value.
• The multi-year vesting schedule (12 equal quarterly installments over three years) incentivizes long-term executive retention and sustained performance.

Negatives

• The RSUs are contingent rights and do not represent immediate cash compensation or direct stock ownership until they vest.

Risks

• The ultimate value of the granted RSUs is directly tied to the future market performance of GoodRx's Class A common stock, exposing the CEO to market volatility.
• Vesting of the RSUs is subject to continued service, meaning the CEO must remain employed through each vesting date to realize the full value of the grant.

Future Outlook

The grant of Restricted Stock Units with a multi-year vesting schedule signals a long-term commitment to the company's future performance and is a key component of executive retention strategy.

Management Comments

• Wendy Lynn Barnes is identified as the Chief Executive Officer and President of GoodRx Holdings, Inc.
• The restricted stock units will vest ratably in 12 equal quarterly installments, with the first vesting occurring on April 15, 2026, and subject to continued service through each applicable vesting date.

Industry Context

StockSavvy.ai notes that executive compensation through equity grants like RSUs is a standard practice across the technology and healthcare sectors. This strategy aims to align leadership incentives with shareholder returns and long-term company growth, consistent with typical executive retention strategies in competitive industries.

Comparison to Industry Standards

• The grant of 1,331,557 RSUs to a CEO is a substantial equity award, comparable in scale to grants observed at similar-sized tech-enabled healthcare companies such as Teladoc Health or Hims & Hers Health, where significant equity components are common in executive compensation to incentivize long-term performance.
• The 3-year quarterly vesting schedule is a common industry practice, balancing immediate incentive with long-term commitment, similar to vesting schedules for senior executives at major technology companies like Amazon or Google.

Stakeholder Impact

• Shareholders: The grant aligns the CEO's financial incentives with the long-term performance of the company's stock, potentially benefiting shareholders if the stock price appreciates.
• Employees: The CEO's continued commitment, incentivized by the RSU grant, can provide stability and strategic direction for employees.

Next Steps

• The first tranche of the Restricted Stock Units is scheduled to vest on April 15, 2026.
• Subsequent vesting will occur in 11 additional equal quarterly installments, subject to continued service through each applicable vesting date.

Key Dates

Recommendation

The filing reports a standard executive equity grant, which is generally a positive for aligning management incentives with shareholder interests. However, it does not provide new operational or financial performance data to warrant a change in investment stance. It reinforces a 'hold' position, acknowledging the long-term commitment of leadership without indicating immediate catalysts for significant price movement.

Keywords

GoodRx, GDRX, SEC Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Beneficial Ownership, Wendy Lynn Barnes, CEO, Stock Grant